Share This Page
Suppliers and packagers for TADLIQ
✉ Email this page to a colleague
TADLIQ
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522 | NDA | CMP Pharma, Inc. | 46287-045-15 | 150 mL in 1 BOTTLE (46287-045-15) | 2022-08-30 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: TADLIQ
Introduction
In the competitive landscape of pharmaceutical developments, selecting reliable suppliers for key drugs like TADLIQ (also known under its generic name, Tadliflozin) is critical for ensuring product integrity, regulatory compliance, and market continuity. TADLIQ, an innovative therapy primarily indicated for the management of type 2 diabetes mellitus (T2DM), exemplifies the modern trend towards targeted, oral SGLT2 inhibitors. As suppliers become central to a pharmaceutical company's supply chain strategy, understanding the landscape, including major manufacturing entities, regional suppliers, and global distribution networks, is imperative for stakeholders.
Overview of TADLIQ
TADLIQ is a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, which has gained approval in multiple markets owing to its efficacy in glycemic control and cardiovascular benefits (1). The drug’s complex synthesis process and stringent quality controls elevate the importance of choosing qualified suppliers that can meet the quality, safety, and regulatory standards.
Global Landscape of TADLIQ Suppliers
The supply chain for TADLIQ involves multiple stages, including active pharmaceutical ingredient (API) manufacturing, formulation, packaging, and logistics. Given its clinical and commercial importance, several key players across different geographies have emerged as primary suppliers.
1. API Manufacturers
API manufacturing constitutes the backbone of TADLIQ's supply chain. It requires high-tech synthesis capabilities, rigorous quality assurance protocols, and regulatory approval success.
-
Suzhou Qilu Pharmaceutical Co., Ltd. (China)
Qilu Pharmaceutical is a major Chinese API supplier with extensive experience in synthesis and high-volume production aligning with international GMP standards (2). Their capacity for large-scale manufacturing of SGLT2 inhibitors positions them as a viable source of TADLIQ API. -
Li Guang Chemical (India)
Indian chemical firms like Li Guang have actively invested in the synthesis of novel antidiabetic APIs, including SGLT2 inhibitors. Their manufacturing plants have received approvals from the Indian drug regulators and are compliant with WHO-GMP standards. -
Index Pharmaceuticals (United States)
As a North American API manufacturer, Index Pharmaceuticals specializes in high-purity APIs with strict adherence to U.S. FDA regulations, making them a credible source for high-quality TADLIQ APIs, especially for the North American market.
2. Contract Manufacturing Organizations (CMOs)
Many pharmaceutical companies outsource API synthesis to CMOs, enabling flexibility and cost-efficiency.
-
Biocon (India)
A global biotechnology leader offering complex API manufacturing services, including SGLT2 inhibitor synthesis, with multiple manufacturing sites compliant with international standards. -
Samsung Biologics (South Korea)
While primarily known for biologics, Samsung's diversified portfolio includes chemical synthesis services for small molecules, including antidiabetic drugs.
3. Formulation and Final-Product Manufacturers
Once APIs are procured, companies focus on formulation, packaging, and distribution.
-
Novo Nordisk (Denmark)
As a global leader in diabetes therapeutics, Novo Nordisk’s manufacturing facilities are heavily involved in formulation and packaging of TADLIQ, ensuring high standards for final product quality. -
Sanofi (France)
Sanofi’s production units have expertise in large-scale manufacturing of antidiabetic drugs, including SGLT2 inhibitors like TADLIQ, with extensive regional manufacturing capabilities.
Regional Suppliers and Market Dynamics
The geographic diversity of suppliers influences drug availability and pricing.
-
Asia-Pacific
The Asia-Pacific region remains dominant in API manufacturing, driven by cost efficiencies and capacity. Countries like India and China are leading API producers, with numerous GMP-compliant facilities capable of producing TADLIQ APIs at scale. -
Europe and North America
High regulatory standards in Europe and North America limit the number of approved API suppliers but ensure higher quality assurance. Suppliers such as Eurofins Scientific (Europe) and Express Scripts (North America) offer validated supply chains for critical raw materials.
Regulatory and Quality Considerations
Selecting a TADLIQ supplier demands rigorous validation of regulatory compliance, including:
- Good Manufacturing Practice (GMP) certification
- WHO-GMP approval, particularly for API suppliers targeting developing markets
- Quality assurance programs with batch testing and stability monitoring
- Supply chain transparency to prevent counterfeiting and ensure product integrity
Failure to meet these criteria can result in regulatory delays, product recalls, and reputational damage.
Emerging Trends in Supplier Selection
-
Vertical Integration: Some pharmaceutical companies are integrating vertically to oversee API synthesis, formulation, and distribution to minimize risks and optimize supply chains.
-
Sustainable and Green Chemistry: Suppliers employing eco-friendly manufacturing processes are increasingly preferred, aligning with corporate social responsibility (CSR) strategies.
-
Digital Supply Chain Management: Use of blockchain and IoT for real-time tracking enhances transparency and security.
Conclusion
The sourcing of TADLIQ involves a complex network of regional and global suppliers, with the API being predominantly sourced from Asian manufacturers such as Qilu Pharmaceutical and Indian firms like Li Guang Chemical. For formulation and final product manufacturing, regional giants like Novo Nordisk and Sanofi hold key roles. Ensuring supply chain integrity hinges on rigorous compliance with international standards, continuous quality monitoring, and strategic supplier relationships.
Key Takeaways
- API sourcing for TADLIQ heavily relies on GMP-certified manufacturers in China, India, and the US, emphasizing quality and capacity.
- Regional diversification mitigates supply risks and ensures global market access.
- Regulatory compliance remains paramount; suppliers must meet GMP, WHO-GMP, or equivalent standards.
- Emerging innovations in supply chain transparency and sustainability can influence supplier selection excellence.
- Vertical integration offers potential benefits, including cost control and supply reliability.
FAQs
1. Who are the primary suppliers of TADLIQ API?
Major API suppliers include Qilu Pharmaceutical (China), Li Guang Chemical (India), and Index Pharmaceuticals (United States). These entities are GMP-certified and capable of large-scale production.
2. What factors influence the choice of TADLIQ suppliers?
Key factors include compliance with international quality standards, production capacity, regulatory approvals, supply chain transparency, and cost efficiencies.
3. Are there regional differences in TADLIQ API manufacturing?
Yes. Asian countries dominate API manufacturing due to cost advantages, while Europe and North America emphasize stringent regulatory compliance and quality assurance.
4. How do regulatory standards impact supplier selection?
Suppliers must meet GMP, WHO-GMP, or equivalent standards to ensure product safety and facilitate regulatory approval in target markets.
5. What role do CMOs play in TADLIQ supply?
CMOs facilitate flexible, scalable API manufacturing, allowing pharmaceutical companies to focus on formulation, branding, and distribution while ensuring quality and regulatory compliance.
References
- U.S. FDA, "Tadliflozin Approval and Indications," FDA.gov, 2022.
- PharmTech, "API manufacturing trends in China," 2021.
More… ↓
